Here are the 10-K annual reports from Exact Sciences Corp (EXAS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EXAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXAS filings page.
Exact Sciences Corporation files its annual report describing strong growth in cancer diagnostics and a pending cash acquisition by Abbott Laboratories. In 2025 the company delivered more than 5.5 million test results, grew revenue 18%, and generated $491.4 million in operating cash flow.
Exact launched next‑generation products including the FDA‑approved Cologuard Plus colorectal screening test, the Oncodetect MRD test, and the Cancerguard multi‑cancer blood test, while securing Medicare reimbursement for Oncodetect. A major focus is an Agreement and Plan of Merger under which each share will be converted into $105.00 in cash, subject to stockholder approval and regulatory clearances, with a potential termination fee of about $628.7 million if the deal fails under specified circumstances.